Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL29356997 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL8255 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL982189 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29438823 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL7097505 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL236666 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5147095 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958766 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL31174198 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112656761-B | Oil-soluble slow-release injection preparation of low-irritation aripiprazole prodrug and preparation method thereof | 河南合智医药科技有限公司 | 2023-09-08 | — | — | CN | claimed |
| US-12605449-B2 | Drug-clay mineral complex containing phospholipid and oral administration composition including same | KOREA INSTITUTE OF GEOSCIENCE AND MINERAL RESOURCES (KR) | 2026-04-21 | — | — | US | disclosed |
| CN-121574093-A | Aripiprazole-2, 3-dihydroxybenzoic acid-hydrate crystal form and preparation method thereof | 鲁南制药集团股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250268892-A1 | TREATMENT OF CANCER USING ARIPIPRAZOLE AND ANTICANCER AGENT | VSPharm Tech Co., Ltd. (KR) | 2025-08-28 | — | — | US | disclosed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250108047-A1 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-03 | — | — | US | disclosed |
| CN-114644588-B | Crystallization method of aripiprazole crystal form B | 天津大学 | 2024-05-07 | — | — | CN | disclosed |
| EP-4347008-A1 | MAJOR DEPRESSIVE DISORDER OR PERSISTENT DEPRESSIVE DISORDER PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | Actipulse Neuroscience Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4327872-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS | Alkermes Pharma Ireland Limited (IE) | 2024-02-28 | — | — | EP | disclosed |
| US-20240058327-A1 | Pharmaceutical Compositions Comprising Sorbitan Esters | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-02-22 | — | — | US | disclosed |
| WO-2022245768-A1 | MAJOR DEPRESSIVE DISORDER OR PERSISTENT DEPRESSIVE DISORDER PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | ACTIPULSE NEUROSCIENCE INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-108069900-B | Preparation method and application of aripiprazole hydrochloride | 齐鲁制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022171513-A1 | METHOD FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING ARIPIPRAZOLE | WARSZAWSKIE ZAKŁADY FARMACEUTYCZNE POLFA S.A. (PL) | 2022-08-18 | — | — | WO | disclosed |
| EP-4043008-A1 | METHOD FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING ARIPIPRAZOLE | Warszawskie Zaklady Farmaceutyczne Polfa S.A. (PL) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022154476-A1 | ORAL DISINTEGRATING FILM WITH QR CODE APPLIED THERETO AND METHOD FOR PREPARING SAME USING 3D PRINTING TECHNOLOGY | 아주대학교산학협력단 | 2022-07-21 | — | — | WO | disclosed |
| CN-114644588-A | Crystallization method of aripiprazole B crystal form | 天津大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-114344303-A | Novel psychotropic drug solid dispersion and preparation method and application thereof | 江苏海洋大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-106674103-B | Preparation method of aripiprazole new crystal form alpha | 万全万特制药江苏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-109251172-B | Synthesis method of aripiprazole | 暨明医药科技（苏州）有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114177868-A | Preparation method and device of aripiprazole | 辰欣药业股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | DRD2 46/4885HTR1A 16/4885HTR2A 12/4885 |
| US-20250108047-A1 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS | CYP2C19, ATP6V1B2, CYP2D6 | DRD2 464/4885HTR1A 17/4885HTR2A 108/4885 |
| US-12605449-B2 | Drug-clay mineral complex containing phospholipid and oral administration composition including same | TOP1, ABCB11, PCTP | DRD2 2689/4885HTR1A 1627/4885HTR2A 2633/4885 |
| US-20240058327-A1 | Pharmaceutical Compositions Comprising Sorbitan Esters | SORBS1, ABCG2, FABP7 | DRD2 280/4885HTR1A 894/4885HTR2A 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.